How are you counseling your patients with ALS taking sodium phenylbutyrate and taurursodiol on continuing treatment in light of the negative phase 3 trial results?  

AMX0035 also known as phenylbutyrate and taurursodiol received accelerated approval from the FDA in 9/2022 following a phase II trial demonstrating a preliminary signal of efficacy. A larger phase III placebo-controlled trial (PHOENIX trial) with >600 subjects was recently completed and, unfortun...